AbbVie sees 2014 approval of hepatitis drugs, shares rise
AbbVie Inc issued a cautious 2014 profit forecast, but said it expects U.S. approval this year for its potentially lucrative new all-oral treatment for hepatitis C, sending its shares up 3.4 percent.
No comments:
Post a Comment